Who are Oxsoralen-Ultra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Arava, Hexalen, Prilosec, Inderal, Bovizole, Omeprazol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methoxsalen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Oxsoralen-Ultra — Competitive Intelligence Brief

Oxsoralen-Ultra (METHOXSALEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photoactivated Radical Generator [EPC]. Area: Oncology.

marketed Photoactivated Radical Generator [EPC] Cytochrome P450 1A2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oxsoralen-Ultra (METHOXSALEN) — Bausch Health. Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxsoralen-Ultra TARGET	METHOXSALEN	Bausch Health	marketed	Photoactivated Radical Generator [EPC]	Cytochrome P450 1A2	1954-01-01
Arava	LEFLUNOMIDE	Sanofi	marketed	Antirheumatic Agent [EPC]	Cytochrome P450 1A2	1998-01-01
Hexalen	ALTRETAMINE	Eisai	marketed	Alkylating Drug	Cytochrome P450 1A2	1990-01-01
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	marketed	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Bovizole	THIABENDAZOLE		marketed	Anthelmintic	Cytochrome P450 1A2	1967-01-01
Omeprazol	Omeprazol	RenJi Hospital	marketed		ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-12-08 — Prilosec · 10835488 · Formulation · US
2036-12-08 — Prilosec · 10076494 · Formulation · US

Sponsor landscape (Photoactivated Radical Generator [EPC] class)

Bausch Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxsoralen-Ultra — Competitive Intelligence Brief. https://druglandscape.com/ci/methoxsalen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab